Davis M R, Shamoon H
Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461.
J Clin Endocrinol Metab. 1991 Apr;72(4):788-92. doi: 10.1210/jcem-72-4-788.
Counterregulatory hormone responses were evaluated in a 37-yr-old woman before and after removal of a benign insulin-producing islet cell tumor. Counterregulatory hormone concentrations were measured during a glucose clamp with graded reductions of plasma glucose from 5.2 to 2.6 mmol/L. In the study before surgery, the increase in plasma epinephrine concentration was markedly blunted (by greater than 90%) compared to that in the study after surgery. The peak plasma norepinephrine concentration was similarly reduced by 71%, and plasma cortisol by 63%. In addition, the glycemic thresholds for secretion of the counterregulatory hormones were lower before removal of the tumor. Peak plasma GH responses were equivalent before and after surgery, but the threshold for GH secretion was 21% lower in the first hypoglycemia study. We conclude 1) that there is evidence for abnormal glucose counterregulatory hormone secretion in this patient, which may contribute to the pathogenesis of hypoglycemia seen in patients with insulinoma; 2) the reversal of reduced counterregulatory hormone secretion after tumor resection suggests that these defective hormonal responses may be related to recurrent hypoglycemia, persistent hyperinsulinemia, or both; and 3) that abnormal glucose counterregulation may exist in the absence of type 1 diabetes.
在一名37岁女性切除良性胰岛素分泌性胰岛细胞瘤前后,对其对抗调节激素反应进行了评估。在葡萄糖钳夹期间,随着血浆葡萄糖从5.2mmol/L逐步降至2.6mmol/L,测量了对抗调节激素浓度。在手术前的研究中,与手术后的研究相比,血浆肾上腺素浓度的升高明显减弱(超过90%)。血浆去甲肾上腺素峰值浓度同样降低了71%,血浆皮质醇降低了63%。此外,在肿瘤切除前,对抗调节激素分泌的血糖阈值较低。手术前后血浆生长激素峰值反应相当,但在首次低血糖研究中,生长激素分泌阈值低21%。我们得出以下结论:1)有证据表明该患者存在异常的葡萄糖对抗调节激素分泌,这可能有助于胰岛素瘤患者低血糖的发病机制;2)肿瘤切除后对抗调节激素分泌减少的逆转表明,这些有缺陷的激素反应可能与复发性低血糖、持续性高胰岛素血症或两者有关;3)在无1型糖尿病的情况下可能存在异常的葡萄糖对抗调节。